Patents & Licensing

Focusing on the future growth of Vivera’s various divisions, the Company has filed a number of patent applications for new medical technologies and medical devices. Behind the development of each product is years of expertise, research, design and development focused on bringing the best solutions to market for patients and their providers.

In addition to its own patents, Vivera holds an exclusive global license for the patented and one-of-a-kind sublingual drug delivery system, TABMELT®.

Utilizing the TABMELT® platform, Vivera has begun to lay the groundwork for clinical research trials for a variety of indications with the goal to gain FDA approval via Investigational New Drug (IND) and/or New Drug Application (NDA) pathways to globally commercialize its finished pharmaceutical products.

Vivera's Patents

Country Title Status
United States PHASED INFECTION TESTING METHOD AND APPARATUS Pending
United States INFECTION TESTING METHOD AND APPARATUS Pending
United States SELF-CONTAINED, PORTABLE, SANITIZATION DEVICE AND TELEMEDICINE STATION Pending
United States SECURE SMART DOSING SYSTEM WITH AUTOMATED DELIVERY, MEASUREMENT, AND MANAGEMENT Granted, 2021
United States SMART INHALER DEVICE WITH AUTOMATED DOSE DELIVERY, MEASUREMENT, AND MANAGEMENT Granted, 2021

Licensed Patents

Country Title Status
Australia All Natural, Non-Toxic Sublingual Drug Delivery Systems Granted, 2016
Canada All Natural, Non-Toxic Sublingual Drug Delivery Systems Granted, 2018
Great Britain All Natural, Non-Toxic Sublingual Drug Delivery Systems Granted, 2018
Israel All Natural, Non-Toxic Sublingual Drug Delivery Systems Pending
Japan All Natural, Non-Toxic Sublingual Drug Delivery Systems Pending
Mexico All Natural, Non-Toxic Sublingual Drug Delivery Systems Pending
Russia All Natural, Non-Toxic Sublingual Drug Delivery Systems Granted, 2021
United States All Natural, Non-Toxic Sublingual Drug Delivery Systems Pending